Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187
Go back to Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 240.74 -3.1 (1.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $243.84 | 52 Week High | $160.00 | |||
| Open | $244.55 | 52 Week Low | $95.80 | |||
| Day High | $244.55 | P/E | 44.75 | |||
| Day Low | $238.98 | EPS | $5.38 | |||
| Volume | 2,214,760 | |||||
